Skip to main content
. Author manuscript; available in PMC: 2016 Oct 9.
Published in final edited form as: Support Care Cancer. 2016 Jul 28;24(11):4779–4789. doi: 10.1007/s00520-016-3329-5

Table 3.

Severity of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) at baseline, 1-month, and 1-year time points

Baseline (pre-treatment)
One-month time pointa
One-year time pointb
FACT/GOG-Ntx item Ctx+ Ctx− α c Significance Ctx+ Ctx− α c Significance Ctx+ Ctx− α c Significance
Sensory symptoms
    Numbness/tingling in hands 0.32 (0.9) 0.27 (0.7) 0.050 0.986 1.4 (1.5) 0.27 (0.8) 0.003 0.002 1.3 (1.4) 0.27 (0.9) 0.008 0.001
    Numbness/tingling in feet 0.14 (0.5) 0.41 (1.0) 0.034 0.355 1.5 (1.6) 0.09 (0.3) 0.002 0.001 1.1 (1.4) 0.41 (1.1) 0.016 0.013
    Discomfort in hands 0.27 (0.9) 0.32 (0.7) 0.037 0.473 1.2 (1.5) 0.32 (0.7) 0.012 0.012 0.95 (1.2) 0.55 (1.0) 0.043 0.142
    Discomfort in feet 0.23 (0.5) 0.50 (1.0) 0.035 0.405 1.3 (1.5) 0.59 (1.1) 0.018 0.055 1.9 (1.3) 1.1 (1.5) 0.042 0.608
Motor symptoms
    Joint pain or muscle cramps 0.86 (1.1) 0.91 (1.2) 0.049 0.949 1.4 (1.4) 1.3 (1.2) 0.045 0.844 1.6 (1.3) 1.6 (1.4) 0.044 0.772
    Feel weak all over 0.41 (0.9) 0.27 (0.6) 0.045 0.860 1.6 (1.5) 0.45 (0.7) 0.005 0.003 1.0 (1.1) 0.4 (0.9) 0.016 0.021
    Trouble walking 0.27 (0.6) 0.36 (0.5) 0.030 0.277 0.68 (1.0) 0.68 (0.7) 0.040 0.550 0.67 (1.0) 0.9 (0.9) 0.031 0.296
Auditory symptoms
    Trouble hearing 0.41 (1.1) 0.55 (0.7) 0.024 0.152 0.59 (1.2) 0.59 (0.7) 0.032 0.338 0.55 (1.2) 1.0 (1.0) 0.019 0.071
    Ringing/buzzing in ears 0.23 (0.8) 0.00 (0.0) 0.027 0.153 0.59 (1.0) 0.05 (0.2) 0.010 0.009 0.55 (0.9) 0.05 (0.2) 0.014 0.018
Functional symptoms
    Trouble buttoning buttons 0.23 (0.8) 0.00 (0.0) 0.026 0.153 0.55 (1.1) 0.00 (0.0) 0.006 0.004 0.55 (0.9) 0.00 (0.0) 0.004 0.002
    Trouble feeling the shape of small objects in hand 0.32 (1.0) 0.32 (0.7) 0.034 0.352 0.64 (0.7) 0.41 (0.7) 0.022 0.141 0.45 (0.7) 0.55 (1.1) 0.048 0.895
Total scores
    Sensory domain 0.95 (2.4) 1.5 (2.9) 0.042 0.656 5.4 (5.6) 1.3 (1.8) 0.005 0.006 4.8 (3.9) 2.3 (3.1) 0.015 0.021
    Motor domain 1.6 (2.7) 1.5 (1.8) 0.041 0.575 3.6 (3.0) 2.1 (1.9) 0.019 0.110 3.1 (2.8) 2.5 (2.8) 0.036 0.419
    Hearing domain 0.68 (1.5) 0.91 (1.0) 0.021 0.127 1.3 (1.9) 1.3 (1.3) 0.036 0.524 1.2 (1.8) 1.8 (1.8) 0.028 0.157
    Functional domain 0.45 (1.7) 0.00 (0.0) 0.025 0.153 1.1 (2.0) 0.05 (0.2) 0.009 0.007 1.1 (1.7) 0.05 (0.2) 0.006 0.004
    Total FACT-GOG/Ntx score 3.7 (6.8) 3.9 (4.1) 0.047 0.894 11.4 (10.3) 4.7 (3.4) 0.017 0.034 9.9 (8.3) 6.7 (5.5) 0.022 0.148

Note Values in italics are statistically-significant

The severity of CIPN-sx were expressed as mean (SD) FACT/GOG-Ntx scores. Differences between in the distributions of FACT/GOG-Ntx scores between Ctx+ and Ctx− at each time point were tested using Mann-Whitney U tests, (α=0.05). Differences between total FACT/GOG-Ntx scores were compared using independent samples t-tests

Ctx+ women with breast cancer treated with surgery and/or radiation and chemotherapy, Ctx− women with breast cancer treated with surgery and/or radiation but no chemotherapy

a

One month following chemotherapy completion or yoked interval for Ctx−

b

One year following one-month time point.

c

Values represent Benjamin-Hochberg corrected alpha (α) levels used to reduce the risk of a type I error during multiple comparisons